<DOC>
	<DOCNO>NCT01056718</DOCNO>
	<brief_summary>The goal pilot study effectively treat hypertension subject either know newly diagnose hypertension concurrent evidence diastolic dysfunction . Due unique property nebivolol , hypothesize improvement leave ventricular ( LV ) systolic diastolic function manifest increase exercise capacity patient population primarily LV diastolic dysfunction . The present study perform determine effect nebivolol blood pressure , exercise tolerance parameter leave ventricular systolic diastolic function group hypertensive patient echocardiographic evidence diastolic dysfunction .</brief_summary>
	<brief_title>Effects Nebivolol Exercise Tolerance Left Ventricular Systolic Diastolic Function</brief_title>
	<detailed_description>Prior initiation Nebivolol 10 week Nebivolol therapy , subject undergo rest 2D echocardiogram include routine sample mitral valve ( MV ) inflow LV tissue Doppler imaging well symptom limited exercise treadmill stress test echocardiographic imaging . Primary endpoint 1 ) change systolic blood pressure 10 week treatment 2 ) change exercise capacity determine exercise duration metabolic equivalent ( MET ) level treatment . Secondary endpoint change exercise hemodynamics Doppler echocardiographic parameter LV systolic diastolic function quality life 10 week nebivolol treatment . Subjects complete EuroQol ( EQ-SD ) Quality Life questionnaire standardized measure health status develop EuroQol group simple general measure health baseline conclusion 10 week trial period .</detailed_description>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Diagnosis ( new establish ) hypertension , define serial measurement &gt; /= 140/90 Evidence diastolic dysfunction echocardiography measure tissue Doppler Severe bronchospastic disease/ reactive airway disease Inability tolerate beta blocker therapy include : &gt; 1st degree atrioventricular ( AV ) block , symptomatic hypotension , symptomatic bradycardia , Subjects physical limitation would prevent participate exercise treadmill test Age &lt; 18 &gt; 90 year Those life expectancy &lt; 1 year Subjects class III/IV New York Heart Association ( NYHA ) heart failure symptoms Chronic Kidney Disease 3 great ( CrCl &lt; 30 cc/min ) Subjects active ischemia evidence ischemia initial stress echocardiography</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diastolic Function</keyword>
	<keyword>Nebivolol</keyword>
</DOC>